In September 2019 , the FDA approved Rybelsus , the first oral GLP-1 receptor agonist, available in 3 mg (starter dose), 7 mg, and 14 mg daily tablets
A recent study published in the Annals of the Rheumatic Diseases found that a class of medications known as GLP-1 receptor agonists (GLP-1 RAs) may significantly ease symptoms of fibromyalgia
What to inject: 3.0 mL reconstitution: 7.5 units once weekly 2.0 mL reconstitution: 5 units once weekly 4.0 mL reconstitution: 10 units once weekly What to expect: Mild appetite suppression is common by week 2
Microdosing Retatrutide Split dosing for the triple-agonist investigational drug
Its important to note that while the two drugs are similar in purpose, their mechanisms and results can vary significantly
Retrieved from Dailey, R., Romo, L., Myer, S., et al